Immunogen Inc. (IMGN) PT Raised to $4 at SVB Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Immunogen Inc. (IMGN) PT Raised to $9 at H.C. Wainwright
December 17, 2019 11:13 AM ESTH.C. Wainwright analyst Debjit Chattopadhyay raised the price target on Immunogen Inc. (NASDAQ: IMGN) to $9.00 (from $5.00) while maintaining a Buy rating.
compelling regulatory advance that they did not anticipate.... MorePre-Open 12/17: (TGE) (IMGN) (JBL) Higher (PTI) (MEIP) (CLVS) Lower (more...)
December 17, 2019 9:35 AM ESTToday's Pre-Open Movers
Proteostasis Therapeutics, Inc. (NASDAQ: PTI) 42.5% LOWER; announced positive topline results from the Company's global, multicenter, randomized, placebo-controlled, 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations in F508del homozygous and heterozygous CF subjects 18 years of age and older.
MEI Pharma, Inc. (NASDAQ: MEIP) 22.5% LOWER; announced today that it has priced the underwritten public offering of 28,125,000 shares of its common stock at $1.60 per share for total gross... More
Immunogen (IMGN) Climbs 37% Pre Open
December 17, 2019 6:45 AM ESTImmunogen (NASDAQ: IMGN) climbed 37% pre-open after announcing that FDA has advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval for mirvetuximab soravtansine.
... MoreImmunogen (IMGN) Reports Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
December 17, 2019 6:31 AM ESTImmunoGen Inc., (NASDAQ: IMGN) today announced that the U.S. Food and Drug Administration (FDA) has advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval for mirvetuximab soravtansine. Based on this guidance, the company will initiate SORAYA, a pivotal trial to evaluate mirvetuximab monotherapy in women with folate receptor alpha (FR)-high... More
